Market Overview

UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results

Share:
Related PCRX
Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report?
Leerink Presents: Your 2017 Biopharma Catalyst Tracker

In a report published Thursday, Bank of America analyst Steve Byrne reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target from $86.00 to $104.00.

In the report, Bank of America noted, “We are raising our PO to $104 (from $86) based on positive results from our Exparel survey, including a meaningful change in the outlook from anesthesiologists and expectations for significant revenue growth. We see upside from use in the nerve block indication (March 5, 2015 PDUFA date) as anesthesiologists in our survey stated they would use Exparel in roughly half of their nerve block procedures if approved.

"We modestly adjusted our peak market share in nerve block to 25% (from 20%) and increased our 2021 peak sales to $2.3bn (from $2.1bn), which assumes some IP extension potential (spray based technology would extend IP to 2031) and expansion of PCRX' manufacturing capacity (readily replicable in our view). We see upside from other DepoFoam–derived products such as NSAIDs.”

Pacira Pharmaceuticals closed on Wednesday at $85.14.

Latest Ratings for PCRX

DateFirmActionFromTo
Apr 2017RBC CapitalInitiates Coverage OnOutperform
Mar 2017WedbushReiteratesOutperform
Feb 2017Canaccord GenuityInitiates Coverage OnBuyBuy

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Bank of America Steve ByrneAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

View Comments and Join the Discussion!